Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Founded in 1996, Collgard Biopharmaceuticals, the tissue therapeutics company, is a privately-held, clinical-stage
company, developing drug treatments that target disease progression by directly influencing the tissue regeneration
process.
Collgard is developing therapeutic solutions for several clinical indications with significant unmet clinical needs. These
solutions are based on highly specific control of the tissue repair process. Current programmes target the following
indications: selected cancers, vascular restenosis, end-organ fibrosis and dermal fibroproliferative disorders.